Cargando…
Interferons in COVID-19: missed opportunities to prove efficacy in clinical phase III trials?
Interferons were repeatedly used in the therapy of COVID-19 due to their antiviral effects. Three recently published randomized controlled clinical phase III trials (WHO SOLIDARITY, ACTT-3, and SPRINTER) missed their primary objectives, i.e., a significant therapeutic effect of interferons was not d...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10263057/ https://www.ncbi.nlm.nih.gov/pubmed/37324124 http://dx.doi.org/10.3389/fmed.2023.1198576 |